現任中(zhōng)國(guó)醫(yī)學(xué)科(kē)學(xué)院病原生物(wù)學(xué)研究所副所長(cháng)，克裏斯托弗·梅裏埃實驗室副主任，中(zhōng)國(guó)醫(yī)學(xué)科(kē)學(xué)院呼吸道疾病病原組重點實驗室（培育）主任，中(zhōng)國(guó)醫(yī)學(xué)科(kē)學(xué)院醫(yī)學(xué)病原微生物(wù)菌（毒）種保藏分(fēn)中(zhōng)心主任。
入選2012年度教育部新(xīn)世紀優秀人才培養計劃和2021年度中(zhōng)組部高層次人才培養計劃。牽頭承擔國(guó)家科(kē)技(jì )重大專項等多(duō)項課題。以第一和通訊（含共同）作(zuò)者發表在Lancet、JAMA、Am J Respir Crit Care Med、Emerg Infect Dis、mSystems、和Clin Microbiol Infect等SCI收錄雜志(zhì)發表50餘篇，被多(duō)部國(guó)際指南、專利和政策文(wén)件參引。是國(guó)家人間傳染的病原微生物(wù)實驗室生物(wù)安(ān)全評審專家委員會委員，任中(zhōng)華預防醫(yī)學(xué)會生物(wù)信息學(xué)分(fēn)會常委兼秘書長(cháng)、中(zhōng)華預防醫(yī)學(xué)會生物(wù)安(ān)全分(fēn)會副主任委員、中(zhōng)國(guó)女醫(yī)師協會公(gōng)共衛生專業委員會副主任委員，是《中(zhōng)華實驗和臨床病毒學(xué)雜志(zhì)》編、《病毒學(xué)報》、《中(zhōng)華微生物(wù)學(xué)與免疫學(xué)》和《中(zhōng)華預防醫(yī)學(xué)雜志(zhì)》編輯委員會委員。
研究成果入選“中(zhōng)國(guó)2020年度“中(zhōng)國(guó)十大醫(yī)學(xué)科(kē)技(jì )新(xīn)聞”、2020年度“十大醫(yī)學(xué)進展”以及“中(zhōng)國(guó)2020年度重要醫(yī)學(xué)進展“。獲2015年和2016年教育部高等學(xué)校科(kē)學(xué)研究優秀成果獎科(kē)技(jì )進步二等獎和一等獎（第二完成人）等省部級獎4項。入選2022年科(kē)睿唯安(ān)全球高被引科(kē)學(xué)家以及斯坦福大學(xué)全球前2%頂尖科(kē)學(xué)家榜單、2017年度北京協和醫(yī)學(xué)院優秀教師、2018年度中(zhōng)國(guó)醫(yī)學(xué)科(kē)學(xué)院-梅裏埃研究院青年科(kē)學(xué)家獎、2019年度中(zhōng)國(guó)女醫(yī)師協會五洲女子科(kē)技(jì )獎基礎醫(yī)學(xué)科(kē)研創新(xīn)獎和2023年北京市教育系統服務(wù)育人先鋒。

主要從事呼吸道感染病原組和緻病機制研究

1.    國(guó)家重點研發項目，植物(wù)乳杆菌GUANKE菌株抗新(xīn)冠病毒作(zuò)用(yòng)研究（2023YFC0871200）2013.011-2013.12子課題負責人
2.    國(guó)家科(kē)技(jì )重大專項項目，急性呼吸道傳染病病原譜和流行規律及重要病原變異變遷特征研究（課題編号2017ZX10103004），2017-2020  項目負責人
3.    國(guó)家科(kē)技(jì )重大專項項目，呼吸道感染病原體(tǐ)深度測序組學(xué)鑒定技(jì )術研究（課題編号 2018ZX10305409-001-002）， 2018-2020  任務(wù)負責人
4.    北京市自然基金重點項目，基于納米孔測序的病原體(tǐ)快速鑒定及應用(yòng)技(jì )術研究（課題編号Z19J00057），2019-2023  子課題負責人
5.    國(guó)家科(kē)技(jì )重大專項項目，呼吸道病毒性傳染病病原譜流行規律及變異研究（課題編号2012ZX10004-206），2012-2015  課題負責人
6.    國(guó)家科(kē)技(jì )重大專項項目，呼吸道病毒性傳染病病原譜流行規律及變異研究（課題編号2009ZX10004-206），2009-2010   課題負責人

# Co-first author; *Co-corresponding author
1.    He Y#, Ma W#, Dang S#, Chen L, Zhang R, Mei S, Wei X, Lv Q, Peng B, Chen J, Kong D, Sun Y, Tang X, Wu W, Chen Z, Li S, Wan J, Zou X, Li M, Feng T*, Ren L*, Wang J*. Possible recombination between two variants of concern in a COVID-19 patient. Emerg Microbes Infect. 2022 Dec;11(1):552-555. 
2.    Chang L, Zhao L, Xiao Y, Xu T, Chen L, Cai Y, Dong X, Wang C, Xiao X, Ren L*, Wang L*. Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019. Protein Cell. 2022 May 24;14(1):28-36.
3.    Wu M#, Liu J#, Wang X, Zhang X, Liang T, Chen L, Huang T, Li Y, Zheng C, Yang Y, Wang J, Yu X*, Guo L*, Yang J*, Ren L*. Profiling of SARS-CoV-2 neutralizing antibody-associated antigenic peptides signature using proteome microarray. Med Comm (2020). 2023 Sep 3;4(5): e361.
4.    Guo L#, Zhang Q#, Zhong J#, Chen L#, Jiang W#, Huang T, Li Y, Zhang Y, Xu L, Wang X, Xiao Y, Wang Y, Dong X, Dong T, Peng Y, Zhang B, Xie Y, Gao H, Shen Z*, Ren L*, Cheng T*, Wang J*. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages. Emerg Microbes Infect. 2023 Dec;12(1): 2202263.
5.    Zhang S#, Huang W#, Ren L#, Ju X#, Gong M#, Rao J#, Sun L, Li P, Ding Q*, Wang J*, Zhang QC*. Comparison of viral RNA-host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2. Cell Res. 2022 Jan; 32(1):9-23.
6.    Liu X#, Xu F#, Ren L#, Zhao F, Huang Y, Wei L, Wang Y, Wang C, Fan Z, Mei S, Song J, Zhao Z, Cen S, Liang C, Wang J*, Guo F*. MARCH8 inhibits influenza A virus infection by targeting viral M2 protein for ubiquitination-dependent degradation in lysosomes. Nat Commun. 2021 Jul 20;12(1):4427.
7.    Chang L#, Zhao L#, Xiao Y, Xu T, Chen L, Cai Y, Dong X, Wang C, Xiao X, Ren L*, Wang L*. Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019. Protein Cell. 2022 May 24; 14(1): 28-36.
8.    Pang X#, Ren L#, Wu S#, Ma W#, Yang J, Di L, Li J, Xiao Y, Kang L, Du S, Du J, Wang J, Li G, Zhai S, Chen L, Zhou W, Lai S, Gao L, Pan Y*, Wang Q*, Li M*, Wang J*, Huang Y*, Wang J*, COVID-19 Field Response Group, COVID-19 Laboratory Testing Group. Cold-chain food contamination as the possible origin of Covid-19 resurgence in Beijing.  Natl Sci Rev. 2020, 7(12), 1861–1864
9.    Han Z#, Rao J#, Xie Z#, Wang C, Xu B, Qian S, Wang Y, Zhu J, Yang B, Xu F, Lei X, Guo F, Zhao Z, Ren L*, Wang J*. Chemokine (C-X-C motif) Ligand 4 is a Restrictor of Respiratory Syncytial Virus Infection and an Indicator of Clinical Severity. Am J Respir Crit Care Med. 2020. 
10.    Ren L#, Wang Y#, Wu Z#, Xiang Z#, Guo L#, Xu T#, Jiang Y, Xiong Y, Li Y, Li X, Li H, Fan G, Gu X, Xiao Y, Gao H, Xu J, Yang F, Wang X, Wu C, Chen L, Liu Y, Liu B, Yang J, Wang X, Dong J, Li L, Huang C, Zhao J, Hu Y, Cheng Z, Liu L, Qian Z, Qin C*, Jin Q*, Cao B*, Wang J*. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020.133(9):1015-1024.
11.    Huang C#, Wang Y#, Li X#, Ren L#, Zhao J#, Hu Y#, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J*, Cao B*. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395(10223):497-506. 
12.    Guo L#, Ren L#, Yang S#, Xiao M#, Chang D#, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L*, Wang J*. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020: ciaa310.
13.    Li L#, Zhang W#, Hu Y#, Tong X#, Zheng S#, Yang J#, Kong Y#, Ren L#, Wei Q#, Mei H# Hu C#, Tao C#, Yang R#, Wang J#, Yu Y#, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y*, Liu Z*. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020. e2010044. 
14.    Shen Z#, Xiao Y#, Kang L#, Ma W#, Shi L, Zhang L, Zhou Z, Yang J, Zhong J, Yang D, Guo L, Zhang G, Li H, Xu Y, Chen M, Gao Z, Wang J, Ren L*, Li M*. Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients. Clin Infect Dis. 2020. Ciaa 203.
15.    Yu J, Qian S, Liu C, Xiao Y, Xu T, Wang Y, Su H, Chen L, Yuan B, Wang X, Xu B, Yang Y, Shen K, Xie Z, Ren L*, Wang J*. Viral etiology of life-threatening pediatric pneumonia: A matched case-control study. Influenza Other Respir Viruses. 2020. 14(4):452-459.
16.    Ren L#, Fan G#, Wu W#, Guo L#, Wang Y#, Li X#, Wang C, Gu X, Li C, Wang Y, Wang G, Zhou F, Liu Z, Ge Q, Zhang Y, Li H, Zhang L, Xu J, Wang C, Wang J*, Cao B*. Antibody Responses and Clinical Outcomes in Adults Hospitalized with Severe COVID-19: A Post hoc Analysis of LOTUS China Trial. Clin Infect Dis. 2020 Aug 25: ciaa1247.
17.    Zhou Z#, Ren L#, Zhang L, Zhong J, Xiao Y, Jia Z, Guo L, Yang J, Wang C, Jiang S, Yang D, Zhang G, Li H, Chen F, Xu Y, Chen M, Gao Z, Yang J, Dong J, Liu B, Zhang X, Wang W, He K, Jin Q, Li M*, Wang J*. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host Microbe. 2020. 27(6):883-890. e2.
18.    Yu J#, Liu C#, Xiao Y#, Xiang Z, Zhou H, Chen L, Shen K, Xie Z*, Ren L*, Wang J*. Respiratory syncytial virus seasonality, Beijing, China, 2007–2015. Emerg Infect Dis. 2019, 25(6):1127-1135. 
19.    Xiao Y, Zhang L, Yang B, Li M*, Ren L*, Wang J. Application of next generation sequencing technology on contamination monitoring in microbiology laboratory. Biosafety and health. 2019, 1(1): 25-31.
20.    Ren L#, Zhang R#, Rao J, Xiao Y, Zhang Z, Yang B, Cao D, Zhong H, Ning P, Shang Y, Li M*, Gao Z*, Wang J*. Transcriptionally Active Lung Microbiome and Its Association with Bacterial Biomass and Host Inflammatory Status. mSystems. 2018, 3(5). pii:e00199-18.
21.    Yan F#, Xiao Y#, Li M, Zhang H, Zhang R, Zhou H, Shen H, Wang J, Li W*, Ren L*. Metagenomic Analysis Identified Human Rhinovirus B91 Infection in an Adult Suffered Severe Pneumonia. Am J Respir Crit Care Med, 2017, 195(11): 1535-1536. 

1. 王健偉，任麗麗，韓子泊. PF4的抗RSV應用(yòng). 授權日2021年12月3日，專利号ZL201710384729.7  授權公(gōng)告号 CN108926707 B
2. 王健偉，任麗麗，劉怡玮，李建國(guó)，肖豔. 新(xīn)型冠狀病毒SARS-CoV-2 熒光定量PCR 檢測方法及其應用(yòng)，授權日 2023年3月14日，專利号 ZL202010215450.8，授權公(gōng)告号：CN 111394513 B
3. 王健偉，趙振東，任麗麗，黃鶴，朱悅. 一種抗新(xīn)型冠狀病毒SARS-CoV-2的雙特異中(zhōng)和抗體(tǐ)及其應用(yòng). 授權公(gōng)告日：2023年09月05，專利号 ZL 2022 1 0315128.1.， 授權公(gōng)告号CN 114605555 B。

1. 王健偉, 任麗麗, 等. 重要和新(xīn)發現呼吸道及腸道病毒的病原學(xué)研究及其應用(yòng). 2015年度高等學(xué)校科(kē)學(xué)研究優秀成果獎（科(kē)學(xué)技(jì )術）二等獎.
2. 金奇，任麗麗，等. 基于宏基因組學(xué)的新(xīn)型病原體(tǐ)組合篩查鑒定實用(yòng)技(jì )術體(tǐ)系及應用(yòng). 2016年度北高等學(xué)校科(kē)學(xué)研究優秀成果獎（科(kē)學(xué)技(jì )術）一等獎.

團隊累計培養研究生、博士後20人次